NBC News @NBCNews
The same advisory panel rejected the drug in a narrow vote last March. However, the FDA in July took the unusual step of announcing a second advisory committee meeting after the company submitted an additional analysis of its trial data. https://t.co/U7zR4IxKdc — PolitiTweet.org